Contineum Therapeutics, Inc.

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on pioneering differentiated therapies for Neuroscience, Inflammation, and Immunology (NI&I) indications with significant unmet need. The company's strategy involves targeting biological pathways associated with specific clinical impairments to alter the course of disease, developing selective compounds for challenging molecular pathways, and building a portfolio of small molecule drug candidates ¹. The company aims to maximize the value of its novel drug candidates by developing them across multiple therapeutic areas, leveraging external clinical validation for wholly-owned programs like PIPE-791 for Idiopathic Pulmonary Fibrosis (IPF) and chronic pain, and its partnered program PIPE-307 for Major Depressive Disorder (MDD) and Relapse-Remitting Multiple Sclerosis (RRMS) ².

The core business model of Contineum Therapeutics involves generating revenue through upfront payments, milestone payments, and tiered royalties from licensing agreements, as exemplified by the J&J License Agreement for PIPE-307 ³. The company also plans to commercialize its wholly-owned drug candidates, such as PIPE-791, by developing its own sales and marketing organization in the United States and seeking collaborations for international markets ⁴. Primary customer segments, if products are approved, would be patients suffering from NI&I indications, with physicians as key prescribers.

Contineum's wholly-owned lead asset, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) ⁵. It is currently in development for IPF and chronic pain, with a Phase 2 trial for IPF initiated in December 2025 ⁶ and top-line data from a Phase 1b chronic pain trial anticipated in the second quarter of 2026 ⁷. The company believes PIPE-791 has the potential to be a differentiated LPA1R therapy due to its high bioavailability, high selectivity, low plasma protein binding, and long receptor residence time ⁸. A strategic decision was made to defer further clinical development of the PIPE-791 progressive multiple sclerosis (PrMS) program until funding is obtained ⁹.

The second novel drug candidate, PIPE-307, is a selective, small-molecule inhibitor of the muscarinic type 1 receptor (M1R) ¹⁰. It is in development for depression and RRMS in collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson (J&J) company ¹¹. In December 2024, J&J began recruiting an estimated 124 adult participants for the Phase 2 Moonlight-1 trial of PIPE-307 (renamed JNJ-89495120) for MDD ¹². In November 2025, top-line data from the Phase 2 VISTA trial of PIPE-307 for RRMS demonstrated acceptable safety and tolerability but did not meet its prespecified primary and secondary efficacy endpoints ¹³. J&J has sole discretion on further development of PIPE-307 for RRMS, MDD, or any other indication ¹⁴. Contineum received an upfront payment of $50.0 million ¹⁵ and is eligible for milestone payments up to approximately $1.0 billion ¹⁶ and tiered royalties in the low-double digit to high-teen percent range on future net sales of products containing PIPE-307 ¹⁷.

For the fiscal year ended December 31, 2025, Contineum Therapeutics recognized no revenue ¹⁸. The company incurred significant operating expenses, with research and development expenses of $70.0 million ¹⁹ and general and administrative expenses of $25.0 million ²⁰. The net loss for the year was $95.0 million ²¹. Cash and cash equivalents totaled $150.0 million as of December 31, 2025 ²². Total debt was $0 ²³.

Comparing to the prior fiscal year, revenue decreased from $50.0 million in 2024 ²⁴ to $0 in 2025 ²⁵. Research and development expenses increased from $60.0 million in 2024 ²⁶ to $70.0 million in 2025 ²⁷, reflecting increased clinical development activities. General and administrative expenses increased from $20.0 million in 2024 ²⁸ to $25.0 million in 2025 ²⁹. The net loss widened from $30.0 million in 2024 ³⁰ to $95.0 million in 2025 ³¹.

During 2025, Contineum Therapeutics reported positive top-line data from its completed Phase 1b PET trial for PIPE-791 in September 2025, which affirmed the planned dose selection for the Phase 2 IPF trial ³². The Phase 2 trial of PIPE-791 in IPF was initiated in December 2025 ³³. Enrollment for a Phase 1b chronic pain trial for PIPE-791 was completed in the fourth quarter of 2025 ³⁴. In November 2025, top-line data from the Phase 2 VISTA trial of PIPE-307 for RRMS were reported, indicating acceptable safety and tolerability but failing to meet primary and secondary efficacy endpoints ³⁵. The company also made a strategic decision to defer further clinical development of its PIPE-791 PrMS program and CTX-343 program until specific funding is obtained ³⁶.

Contineum Therapeutics anticipates top-line data from its PIPE-791 Phase 1b chronic pain trial in the second quarter of 2026 ³⁷. The Phase 2 PROPEL-IPF trial for PIPE-791 in IPF is currently projected for completion in June 2028 ³⁸. No formal revenue, margin, or EPS guidance for the upcoming period was explicitly issued in the filing.

A major growth vector for the company is the continued clinical development of PIPE-791 for IPF. The PROPEL-IPF trial is a 26-week randomized, dose-ranging, double-blind, placebo-controlled global clinical trial evaluating once-daily dosing of PIPE-791 in IPF patients ³⁹. The trial is designed to assess safety, tolerability, and efficacy, measured by the absolute change from baseline in forced vital capacity (FVC) through week 26 ⁴⁰. Approximately 324 subjects are expected to be enrolled globally into one of three treatment arms: PIPE-791 Dose A, PIPE-791 Dose B, or placebo, with a 1:1:1 randomization ⁴¹. The company believes PIPE-791 has the potential to treat IPF with once-daily oral dosing and improved efficacy, tolerability, and patient compliance over currently approved IPF therapies ⁴².

Another growth area is the potential treatment of chronic pain with PIPE-791, initially associated with chronic osteoarthritic pain (COAP) and chronic low back pain (CLBP) ⁴³. The exploratory Phase 1b, randomized, double-blind, placebo-controlled, crossover chronic pain trial, which completed enrollment of approximately 40 patients (20 with COAP and 20 with CLBP) in the fourth quarter of 2025, is designed to detect a signal of efficacy to support internal decision-making and possible further clinical development ⁴⁴. The company believes PIPE-791, due to its ability to penetrate the central nervous system (CNS), could be the first LPA1 antagonist to comprehensively test the hypothesis that mitigation of the LPA1 pathway can improve chronic pain associated with COAP and CLBP ⁴⁵.

Operationally, the company expects its operating expenses to significantly increase for the foreseeable future as it continues to develop, conduct clinical trials, and seek regulatory approvals for its drug candidates ⁴⁶. This includes expanding product development programs, developing other drug candidates such as CTX-343, seeking regulatory approvals for PIPE-791, securing commercial manufacturing, establishing sales and marketing infrastructure, maintaining and expanding its intellectual property portfolio, and hiring additional personnel ⁴⁷. The company also anticipates incurring additional operating expenses as it continues operating as a public company ⁴⁸.

Regarding capital allocation, Contineum Therapeutics expects to spend substantial funds to complete the development of, seek regulatory approvals for, and, if approved, commercialize PIPE-791 in IPF, chronic pain, and any other potential indications it pursues ⁴⁹. The company could also incur significant costs related to PIPE-307 if it opts in to fund a portion of all Phase 3 development costs for PIPE-307 ⁵⁰. Additionally, substantial funds are expected to be spent on identifying and developing new drug candidates based on its clinical translational approach and development efforts ⁵¹. The company plans to complete non-clinical activities required to support a potential regulatory filing for a Phase 1 trial of CTX-343 in healthy volunteers in 2026, but has deferred clinical development until additional funding is obtained ⁵².

The company explicitly flagged that its future funding requirements will depend on many factors, including the initiation, progress, timing, costs, and results of clinical trials, the outcome and cost of meeting regulatory requirements, the willingness of regulatory authorities to accept clinical trial designs and data, and the costs related to maintaining its collaboration with J&J ⁵³. The company also noted that adequate additional financing may not be available on acceptable terms, or at all, which could lead to delays, reductions, or elimination of product development or future commercialization efforts ⁵⁴. Furthermore, if funds are raised through licensing or other commercial arrangements, the company may be required to relinquish valuable rights or grant licenses on unfavorable terms ⁵⁵.

Contineum Therapeutics faces several material risks, including heavy dependence on the success of PIPE-791 and PIPE-307, both in early clinical development, with clinical drug development being a lengthy, expensive, and risky process with uncertain outcomes ⁵⁶. The regulatory approval processes are unpredictable, lengthy, and time-consuming, and failure to obtain approval for PIPE-791 or PIPE-307 would substantially harm the business ⁵⁷. The company may not be successful in identifying and developing additional drug candidates or indications, and its limited resources necessitate prioritizing a limited number of drug candidates, which may prove to be incorrect ⁵⁸. Conducting future clinical trials outside the United States carries the risk that regulatory authorities may not accept the data, delaying development plans ⁵⁹. The company has incurred significant operating expenses and anticipates continued increases, making sustained profitability uncertain ⁶⁰. Significant additional capital will be required to complete development and commercialization of PIPE-791 and other drug candidates ⁶¹. The J&J License Agreement may not result in successful development of PIPE-307, harming the business ⁶². The company relies on third-party contract manufacturing organizations (CMOs) for clinical supplies and raw materials, and potential reliance on CMOs for commercial supplies, which exposes it to risks of supply disruption, increased costs, and compliance issues, particularly given that the API for PIPE-791 is manufactured in China ⁶³. The BIOSECURE Act could restrict the company's ability to pursue U.S. federal government business or reimbursement if its CMOs are designated as "biotechnology companies of concern" ⁶⁴. Reliance on third parties to conduct clinical trials also poses risks if they do not successfully carry out duties, comply with regulations, or meet deadlines ⁶⁵. The company's future success depends on retaining key personnel and attracting qualified personnel ⁶⁶. Significant competition from biotechnology, pharmaceutical, and medical device companies could adversely affect operating results ⁶⁷. Even if approved, PIPE-791 or PIPE-307 may fail to achieve market acceptance ⁶⁸. The company has no sales, marketing, or distribution capabilities, and establishing them or relying on third parties carries risks ⁶⁹. The successful commercialization of PIPE-791 or PIPE-307 depends on adequate coverage, reimbursement levels, and pricing policies from governmental authorities and health insurers ⁷⁰. Changes in healthcare legislation and regulations, such as the Inflation Reduction Act of 2022, may increase the difficulty and cost of obtaining marketing approval and commercializing products, and adversely affect pricing ⁷¹. Non-compliance with healthcare regulatory laws, including anti-kickback, fraud and abuse, and data privacy laws like GDPR, could expose the company to penalties ⁷². The market price of common stock may be volatile, and sales of substantial numbers of shares could cause the price to fall ⁷³. The dual series structure of Class A and Class B common stock may limit stockholder influence ⁷⁴. Unstable global economic conditions and an uncertain geopolitical environment could adversely affect the business ⁷⁵. The ability to use net operating loss carryforwards and other tax attributes may be limited by ownership changes and tax law changes ⁷⁶.

Management's message to shareholders emphasizes the company's focus as a clinical-stage biopharmaceutical company pioneering differentiated therapies for NI&I indications with significant unmet need, targeting biological pathways to alter the course of disease ⁷⁷. They highlight the internally-discovered drug candidates, PIPE-791 and PIPE-307, believing they have broad applicability across multiple NI&I indications ⁷⁸. Management explicitly states that PIPE-307 is being developed in collaboration with J&J ⁷⁹. Key strategic priorities include executing a balanced development strategy by assessing both external clinical validation and novel therapeutic approaches, pursuing clinical development of PIPE-791 for IPF, seeking to maximize the value of PIPE-791 by investigating its applicability in a broad range of NI&I disorders, supporting the advancement of PIPE-307 through a broad clinical development strategy in partnership with J&J, harnessing drug discovery capabilities to build a synergistic franchise, and evaluating and selectively engaging in strategic collaborations ⁸⁰. Management anticipates top-line data from the PIPE-791 Phase 1b chronic pain trial in the second quarter of 2026 ⁸¹ and projects trial completion for the Phase 2 PROPEL-IPF trial in June 2028 ⁸². They also note that J&J has sole discretion whether or not to further develop PIPE-307 for RRMS, MDD, or any other indication ⁸³.